Urology News and Research

Latest Urology News and Research

Charité begins implementation of MGN1601 clinical phase I/II study in renal cancer

The Charité - Medical University of Berlin has today begun the implementation of the clinical study phase I/II with the renal cancer medication MGN1601 (ASET Study). With this MOLOGEN AG product, an innovative cell-based gene therapy for the treatment of advanced renal cancer is entering the first important test phase.

15 Dec 2010

Watson files generic Exalgo ANDA, confirms patent challenge from Mallinckrodt

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc. – Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Hydromorphone Hydrochloride Extended-release Tablets, 8 mg, 12 mg, and 16 mg.

14 Dec 2010

GTx announces Capesaris proof of concept clinical trail in men with advanced prostate cancer

BETHESDA, Md.,GTx, Inc. this weekend presented results of the Capesaris™ (GTx-758) proof of concept pharmacokinetic-pharmacodynamic (PK/PD) clinical trial at the Annual Meeting of the Society of Urologic Oncology.

14 Dec 2010

NinePoint enters IP licensing agreement with Massachusetts General Hospital

NinePoint Medical, Inc., an emerging leader in the development of in vivo pathology medical devices, today announced it has entered into an intellectual property (IP) licensing agreement with Massachusetts General Hospital (MGH). Under the agreement, NinePoint has certain exclusive rights in multiple fields to 188 patents and patent applications owned by MGH.

13 Dec 2010

Scientists create functioning human intestinal tissue from pluripotent stem cells

For the first time, scientists have created functioning human intestinal tissue in the laboratory from pluripotent stem cells.

13 Dec 2010

Expert discusses androgen deprivation therapy for prostate cancer

A common prostate cancer treatment, the ‘androgen deprivation therapy’ has often been prescribed for low-risk prostate cancer patients. This therapy for treating prostate cancer had previously been blamed for increased risk of cardiovascular disease and heart conditions.

9 Dec 2010

WSJ investigation: A sharp rise in specific prostate therapy parallels high Medicare payments

Roughly one in three Medicare beneficiaries diagnosed with prostate cancer today gets a sophisticated form of radiation therapy called IMRT. …The story behind the sharp rise in the use of IMRT — which stands for intensity-modulated radiation therapy — is about more than just the rapid adoption of a new medical technology.

9 Dec 2010

Researchers develop imaging technology that can accurately identify prostate cancer

Prostate cancer is the most common type of cancer among men, but its diagnosis has up to now been inaccurate and unpleasant. Researchers at Eindhoven University of Technology in the Netherlands, in cooperation with AMC Amsterdam, have developed an imaging technology that can accurately identify tumors.

8 Dec 2010

Watson, Natco confirm development agreement for generic Revlimid

Watson Pharmaceuticals, Inc. and Natco Pharma Limited today confirmed an exclusive, U.S. development and license agreement, to develop and commercialize lenalidomide 5, 10, 15 and 25 mg tablets. The companies also confirmed that Natco has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its lenalidomide 5, 10, 15 and 25 mg product. Natco's lenalidomide tablets are generic versions of Celgene's Revlimid ® Tablets.

7 Dec 2010

Positive results from PROCHIEVE 8% vaginal progesterone gel Phase III trial to reduce preterm birth risk

Columbia Laboratories, Inc. and Watson Pharmaceuticals, Inc. today announced positive top-line results from the PREGNANT Study, a large, global Phase III clinical trial evaluating PROCHIEVE® 8% vaginal progesterone gel to reduce the risk of preterm birth in women with a short cervical length as measured by transvaginal ultrasound at mid-pregnancy.

7 Dec 2010

Wide-scale study of flu vaccine's effectiveness in European children needed

A wide-scale study of the effectiveness of flu vaccine in children is needed in Europe to fully assess the benefits, not only in keeping the kids from getting sick, but limiting the spread of flu to adults.

4 Dec 2010

FDA Advisory Committee votes in favor of expanded use of LAP-BAND gastric band

Allergan, Inc. (NYSE: AGN) today announced the U.S. Food and Drug Administration (FDA) Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee has recommended with an 8-2 vote that the FDA extend the currently approved use of the LAP-BAND® System, Allergan's gastric band, on the basis of a favorable benefit-risk profile for weight reduction in obese adults who have failed more conservative weight reduction alternatives and have a Body Mass Index (BMI) of at least 35 or a BMI ≥30 and at least one comorbid condition.

4 Dec 2010

FDA Advisory Panel recommends approval of Solesta for bowel incontinence

Oceana Therapeutics, a global company focused on acquiring, developing and commercializing best-in-class specialty therapeutics, today announced that the U.S. Food and Drug Administration's (FDA) Gastroenterology and Urology Devices Panel recommended approval of Solesta™ as a treatment for fecal (bowel) incontinence, a condition afflicting many Americans, primarily women.

3 Dec 2010

UC Irvine receives Silver Medal from HHS for supporting organ, tissue donation

UC Irvine Medical Center recently received a Silver Medal of Honor from the U.S. Department of Health & Human Services for its role in supporting organ and tissue donation.

3 Dec 2010

New robotic arm device for early to mid-stage osteoarthritis

A robotic arm device developed to assist orthopedic surgeons with performing partial knee replacement surgery for early to mid-stage osteoarthritis is now available at NewYork-Presbyterian Hospital/Columbia University Medical Center. The technology was approved by the FDA in 2005, and to date nearly 5,000 cases have been performed in the U.S.

3 Dec 2010

Endo acquires Qualitest Pharmaceuticals

Endo Pharmaceuticals (Nasdaq: ENDP) announced today the completion of its acquisition of Qualitest Pharmaceuticals. Endo announced Sept. 28 that it entered into a definitive agreement to acquire Qualitest Pharmaceuticals, a leading, privately held generics company in the U.S., for approximately $1.2 billion in cash.

2 Dec 2010

Medivation, Astellas enroll 1,199 patients in MDV3100 Phase 3 AFFIRM study in advanced prostate cancer

Medivation, Inc. and Astellas Pharma Inc. today announced that patient enrollment was completed on November 15, 2010 in the Phase 3 AFFIRM study of the investigational drug MDV3100, a novel, triple-acting oral androgen receptor antagonist, in patients with advanced prostate cancer who have previously been treated with chemotherapy. The companies also announced that clinical development of MDV3100 in Japan has commenced, with the initiation of patient dosing in a Phase 1-2 clinical study.

30 Nov 2010

Perrigo launches generic Aleve Liquid Gels

Perrigo today announced that it has launched Naproxen Sodium Soft Gels. The product is the generic equivalent of Bayer HealthCare's Aleve® Liquid Gels, 220mg, an OTC analgesic. Aleve® Liquid Gels had sales of approximately $80 million, as measured by Information Resources, Inc. Perrigo believes it is the first to market a store brand version of this product.

29 Nov 2010

Texas Breast Specialists expands breast cancer treatment services

Texas Breast Specialists, part of Texas Oncology, has expanded its breast cancer treatment services in Dallas, McKinney, Bedford, Carrollton, and Plano, Texas to include the mobile Naviscan PEM scanner.

29 Nov 2010

Bref Rhone-Alpes honors EDAP with Best 2010 Product Innovation award for Sonolith i-move lithotripter

EDAP TMS SA, the global leader in therapeutic ultrasound, reported today that its new lithotripter Sonolith i-move received the Best 2010 Product Innovation award by the French economic journal Bref Rhone-Alpes. The award was presented on November 22, 2010 at a gathering of all major local economic and financial partners.

24 Nov 2010

Urology News and Research

Latest Urology News and Research

Charité begins implementation of MGN1601 clinical phase I/II study in renal cancer

Watson files generic Exalgo ANDA, confirms patent challenge from Mallinckrodt

GTx announces Capesaris proof of concept clinical trail in men with advanced prostate cancer

NinePoint enters IP licensing agreement with Massachusetts General Hospital

Scientists create functioning human intestinal tissue from pluripotent stem cells

Expert discusses androgen deprivation therapy for prostate cancer

WSJ investigation: A sharp rise in specific prostate therapy parallels high Medicare payments

Researchers develop imaging technology that can accurately identify prostate cancer

Watson, Natco confirm development agreement for generic Revlimid

Positive results from PROCHIEVE 8% vaginal progesterone gel Phase III trial to reduce preterm birth risk

Wide-scale study of flu vaccine's effectiveness in European children needed

FDA Advisory Committee votes in favor of expanded use of LAP-BAND gastric band

FDA Advisory Panel recommends approval of Solesta for bowel incontinence

UC Irvine receives Silver Medal from HHS for supporting organ, tissue donation

New robotic arm device for early to mid-stage osteoarthritis

Endo acquires Qualitest Pharmaceuticals

Medivation, Astellas enroll 1,199 patients in MDV3100 Phase 3 AFFIRM study in advanced prostate cancer

Perrigo launches generic Aleve Liquid Gels

Texas Breast Specialists expands breast cancer treatment services

Bref Rhone-Alpes honors EDAP with Best 2010 Product Innovation award for Sonolith i-move lithotripter

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Urology News and Research

Latest Urology News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in